MAPT and tauopathy: Unfortunately, the leading mouse models that develop tau pathology (e.g., P301S, P301L) used in preclinical testing of anti-tau therapies have frontotemporal lobar degeneration (FTLD) tauopathies which are structurally different from AD tauopathy, limiting their predictive power for AD clinical trials [65, 66].